Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients
BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.a1792 (Published 26 May 2009) Cite this as: BMJ 2009;338:a1792
- Yutaro Suzuki, psychiatrist and medical researcher1,
- Junzo Watanabe, psychiatrist and medical researcher1,
- Naoki Fukui, psychiatrist and medical researcher1,
- Vural Ozdemir, clinical pharmacologist and bioethics/science policy researcher2,
- Toshiyuki Someya, psychiatrist and medical researcher1
- 1Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 2Département de Médecine Sociale et Préventive, Programmes de Bioéthique, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada
- Correspondence to: T Someya psy{at}med.niigata-u.ac.jp
We report three cases of hypoglycaemia in non-diabetic non-obese Japanese inpatients who had schizophrenia and were being treated with a second generation antipsychotic. The clinical findings of hypoglycaemia emerged typically 2-3 hours after meals in all patients during escalation of the dose of second generation antipsychotic. No other antipsychotic or concomitant drug with a metabolic effect was coadministered.
Case 1—A 27 year old woman who took 400 mg of quetiapine a day complained of dizziness, tremor, and palpitations on day 112 of her inpatient stay. These symptoms worsened with a 600 mg daily dose of quetiapine (day 132). At this point, her blood glucose three hours after lunch was 3.2 mmol/l. Her symptoms …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.